Walgreen Company (WAG), CVS Caremark Corporation (CVS): Why Rite Aid Corporation (RAD) Earnings Could Disappoint Investors

Rite Aid Corporation (NYSE:RAD) will release its quarterly report on Thursday, and investors who’ve bid the stock up to new 52-week highs have to think the news from the drugstore chain will be good. Yet analysts expect that Rite Aid Corporation (NYSE:RAD) earnings will come in negative, and news that the company could be headed back to losses instead of profits might leave shareholders thinking they’ve made too big a bet on Rite Aid’s recovery.

Rite Aid Corporation (NYSE:RAD) has long played a distant No. 3 to its major drugstore-chain competitors, as huge amounts of debt have left its stock languishing in spite of sizable gains from its rivals. Yet despite repeated calls for what many see as Rite Aid’s inevitable failure, it has managed to survive and even post profits recently. How long can the good times for the stock last? Let’s take an early look at what’s been happening with Rite Aid Corporation (NYSE:RAD) over the past quarter and what we’re likely to see in its report.

Stats on Rite Aid

Source: Yahoo! Finance.

Could Rite Aid earnings surprise investors again this quarter?
Analysts have gotten less optimistic about prospects for Rite Aid Corporation (NYSE:RAD) earnings in recent months, widening their August-quarter loss estimates by $0.03 per share and cutting the same amount for their full-year fiscal 2014 profit projections. The stock, though, has climbed substantially, gaining 14% since mid-June.

In its May quarter, Rite Aid posted impressive earnings growth. It reversed a year-ago loss with a profit that was at the top end of previous guidance. As introductions of new generic drugs have been strong lately, Rite Aid Corporation (NYSE:RAD) has enjoyed a margin boost from the lower costs of generics and the greater percentage markups available.

But the stock dropped after its report because its management is cautious about how long those favorable tailwinds can last. In particular, generic-drug introductions are expected to fall in the future. Moreover, the company has had to deal with costs of refinancing debt, with a June offering of $810 million in eight-year notes with a rate of 6.75% to be used to buy back existing debt carrying a much higher 9.5% interest rate. Buying back old bonds through a tender process will cost the company initially, but annual interest savings will be substantial.